Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

634 results about "Red blood cell" patented technology

Red blood cells (RBCs), also referred to as red cells, red blood corpuscles, haematids, erythroid cells or erythrocytes (from Greek erythros for "red" and kytos for "hollow vessel", with -cyte translated as "cell" in modern usage), are the most common type of blood cell and the vertebrate's principal means of delivering oxygen (O₂) to the body tissues—via blood flow through the circulatory system. RBCs take up oxygen in the lungs, or gills of fish, and release it into tissues while squeezing through the body's capillaries.

Blood cell detection method based on improved YOLOv8

The invention relates to the technical field of target detection, and discloses a blood cell detection method based on improved YOLOv8. According to the method, a convolutional attention module (CBAM) is introduced, so that the detection performance of the model on a shielded small target is improved; a new loss function S-MPDIOU is set, so that the accuracy and robustness of the loss function are further improved; the multi-scale feature fusion technology is adopted to better capture blood cell information of different sizes, so that the model can more accurately identify small target platelets; the recall rate is improved by improving a non-maximum suppression (NMS) algorithm, and particularly under the condition of dense blood cells or complex forms, the improved NMS algorithm can more effectively solve the overlapping problem and reduce false detection and missing detection. Through testing, the model can accurately identify and position different types of blood cells such as red blood cells, white blood cells and blood platelets in an image, and a new effective method is provided for blood cell detection.
Owner:HARBIN MEDICAL UNIV DAQING BRANCH

Activin receptor type IIA variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.
Owner:KEROS THERAPEUTICS INC

Traditional Chinese medicine composition with effects of benefiting qi, nourishing blood, invigorating spleen and tonifying kidney and preparation method of traditional Chinese medicine composition

The invention discloses a traditional Chinese medicine composition with the effects of benefiting qi, nourishing blood, invigorating the spleen and tonifying the kidney and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: cistanche, ginseng, American ginseng, astragalus membranaceus, medlar, rhizoma polygonati, oyster peptide, angelica sinensis, radix rehmanniae preparata, donkey-hide gelatin, fructus amomi, pericarpium citri reticulatae, hawthorn, folium cortex eucommiae, radix puerariae, liquorice and the like. The preparation method comprises the following steps: respectively crushing the medicinal materials, dissolving the colla corii asini, mixing, adding water, granulating and the like. The composition can be prepared into various dosage forms such as granules, capsules, tablets, oral liquid and the like. Experiments show that the traditional Chinese medicine composition can effectively improve the symptoms of deficiency of qi and blood (increasing erythrocyte count and hemoglobin content), weakness of spleen and stomach (increasing body weight and improving pepsin activity) and kidney deficiency (reducing creatinine and urea nitrogen content and improving SOD activity), and acute toxicity experiments show that the toxicity is slightly reversible under high dosage, and the safety is good under therapeutic dosage. The traditional Chinese medicine composition has potential application value in the aspect of preparing medicines for benefiting qi, nourishing blood, invigorating spleen and tonifying kidney.
Owner:SHANDONG RENYITANG BIOTECHNOLOGY CO LTD

Anti-aging and whitening pyracantha fortuneana fruit extract prepared by adopting supramolecular solvent and preparation method of pyracantha fortuneana fruit extract

The invention provides an anti-aging and whitening pyracantha fortuneana fruit extract prepared by adopting a supramolecular solvent and a preparation method of the pyracantha fortuneana fruit extract, and relates to the technical field of biological extraction. The preparation method comprises the following steps: by taking betaine as a hydrogen bond acceptor and 1, 3-propylene glycol as a hydrogen bond donor, mixing and self-assembling the betaine and the 1, 3-propylene glycol to form a supramolecular solvent; and the pyracantha fortuneana fruits are extracted by adopting the supramolecular solvent. The pyracantha fortuneana fruit active ingredients are extracted by adopting the supramolecular solvent which is harmless to the skin, so that the irritation of the solvent to the skin can be avoided, the supramolecular solvent can be specifically combined with the active ingredients in the pyracantha fortuneana fruit, and the purity and activity of the active ingredients are improved. The pyracantha fortuneana fruit extract extracted by adopting the supramolecular solvent has better oxidation reduction resistance; generation of non-enzymatic glycosylation intermediate products is inhibited, and saccharification and aging resistance are facilitated; the red blood cell oxidative damage is improved, and the effects of resisting oxidation and relieving are achieved; the whitening mask has an inhibiting effect on elastinase and tyrosinase, and can resist aging, whiten skin, relieve facial pigmentation and brighten the skin.
Owner:GUANGZHOU CUINAKANG BIOTECH CO LTD

Blood component separation system and control method

The invention discloses a blood component separation system and a control method, and belongs to the field of blood separation.The system comprises a centrifugal device, a blood supply pipeline, an air detector valve and a blood pump, a liquid outlet of the centrifugal device is connected with a separation pipeline, and the separation pipeline is sequentially connected with a first plasma bag and a second plasma bag; a centrifugal pressure sensor, a centrifugal high-speed camera and a red blood cell sensor; and the control center comprises a data acquisition module, a data analysis module and a centrifugal control module. The control method comprises steps S1 to S4. Dynamic intelligent regulation and control and automatic control of the blood component centrifugal separation system are achieved, the centrifugal effect is optimized through the image recognition technology, the image recognition technology is superior to the photoelectric recognition technology in the prior art, excessive centrifugation is avoided, meanwhile, the centrifugal quality is guaranteed, and the quality and activity of separated blood components are effectively guaranteed.
Owner:CHENGDU JIAYING MEDICAL PROD

Activin receptor type IIB variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.
Owner:KEROS THERAPEUTICS INC

Continuous blood oxygen monitoring system in extracorporeal circulation and control method thereof

The embodiment of the invention provides a continuous blood oxygen monitoring system in extracorporeal circulation and a control method thereof. The continuous blood oxygen monitoring system comprises a vein sensor, an artery sensor, a blood flow sensor, an oxygen sensor, a carbon dioxide sensor, a controller and a display, the vein sensor monitors the vein blood oxygen saturation degree; the artery sensor monitors arterial oxygen saturation and hematocrit; the blood flow sensor monitors the blood flow of the artery pipeline; the oxygen sensor monitors the oxygen concentration of the oxygenator; the carbon dioxide sensor monitors the carbon dioxide concentration of the oxygenator; the display provides an interaction control, responds to a trigger operation acting on the interaction control, sends an interaction instruction to the controller, and updates information displayed in an interaction interface according to the control of the controller; the controller receives the interaction instruction and executes processing corresponding to the interaction instruction; the processing includes controlling display information of the display; the display information comprises information corresponding to the monitoring parameters. The scheme ensures the safety and effectiveness of the treatment process.
Owner:SHANGHAI FENGYU BIOTECHNOLOGY CO LTD +1

Concentration measurement device

To improve measurement accuracy.A concentration measurement device includes: an absorbance measurement unit configured to measure absorbance in a plurality of different wavelength regions for a mixed liquid in which different liquids are mixed; and a control unit configured to correct a concentration of at least one liquid on the basis of absorbance in the plurality of different wavelength regions. The absorbance measurement unit measures absorbance in two wavelength regions. The absorbance measurement unit measures absorbance in a spectrum. Particles contained in one of the different liquids are different from particles contained in another of the different liquids. Each of the different liquids is a suspension or a solution. The mixed liquid includes a white blood cell suspension and a red blood cell suspension. The control unit calculates a mixing ratio of a liquid mixed in the mixed liquid, from absorbance in the plurality of different wavelength regions. The control unit corrects the absorbance on the basis of a mixing ratio of a liquid mixed in the mixed liquid.
Owner:SONY GROUP CORP

Blood growth factor extraction device and information loading system

The invention belongs to the technical field of medical equipment, and particularly relates to a blood growth factor extraction device and an information loading system.The blood growth factor extraction device comprises a box body used for connecting all components; the blood centrifugal assembly is arranged in the box body, and the blood centrifugal assembly is used for centrifugally removing red blood cells of the blood; the information field assembly is arranged in the box body, the information field assembly is connected with the blood centrifugal assembly, and the information field assembly is used for performing scalar wave action on blood in the blood centrifugal assembly and loading specific life factor information into plasma; the disinfection assembly is arranged in the box body, the disinfection assembly is connected with the blood centrifugal assembly, the disinfection assembly is used for disinfecting test tubes in the blood centrifugal assembly, and it is guaranteed that wound repair factors, blood platelets, growth factors and the like are more easily and sufficiently separated during separation and preparation.
Owner:HANGKE SHANGYI AEROSPACE TECHNOLOGY (BEIJING) CO LTD

Method for detecting hemolysis rate of metaraminol bitartrate injection

The invention discloses a hemolysis rate detection method for metaraminol bitartrate injection, aims to overcome the defects in the prior art, and provides a hemolysis rate detection method capable of eliminating interference on hemolysis rate detection caused by reaction between metaraminol bitartrate injection and red blood cells. The method specifically comprises the following steps: adding metaraminol bitartrate injection into a red blood cell suspension, incubating, repeatedly cleaning uncrushed red blood cells until the supernatant is colorless and transparent, removing the supernatant, performing ultrasonic treatment on the residual red blood cells to crush all the red blood cells, performing centrifugal separation, taking the supernatant, and performing freeze-drying to obtain the red blood cell suspension. The absorbance value is measured on a spectrophotometer, and the hemolysis rate is calculated. Compared with the prior art, the invention provides the detection method based on the improved spectrophotometric method, through special treatment of unbroken red blood cells and combination of ultrasonication and cleaning steps, the problem of applicability of a traditional method in specific drugs is solved, and the accuracy and reliability of detection are greatly improved.
Owner:CHINA INST FOR RADIATION PROTECTION

Red cell membrane with complete structure as well as preparation method and application of red cell membrane

The invention belongs to the technical field of cell engineering and biochemical detection, and particularly relates to an erythrocyte membrane with a complete structure and a preparation method and application thereof. The red blood cells are split by limiting the components of the release liquid, the conditions are mild, protein components such as hemoglobin in the red blood cells can be released, the cell attributes are removed, the integrity of the internal skeleton structure and the activity of the membrane surface antigen are reserved, the complete structure of the red cell membrane is kept, meanwhile, the key blood group antigen on the surface is reserved, and the effect is good. The problem of antigenicity reduction caused by erythrocyte membrane fragmentation is avoided. After the erythrocytes are lysed, the nanoparticles are coupled to the surface of the erythrocyte membrane, so that the agglutination reaction of the erythrocyte membrane under the induction of the antibody can be visualized. The engineering red blood cell biological membrane is preserved by adopting a fixed program, so that the damage of ice crystals to the engineering red blood cell biological membrane can be effectively avoided, the antigenicity of the membrane is not influenced, the membrane can be preserved for a long time at normal temperature, and the shelf life can be prolonged to two years or more.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Biomarker for predicting whether patients suffering from pyotoxic myocardial injury have short-term death risk or not and application of biomarker

PendingCN120748711AHealth-index calculationBiostatisticsLaboratory Test ResultRed blood cell
The invention relates to the technical field of biological and medical diagnosis, in particular to a biomarker for predicting whether a patient suffering from pyotoxic myocardial injury has a short-term death risk or not and application of the biomarker, and the biomarker is the ratio of erythrocyte distribution width to albumin. According to the method, retrospective queue research design is adopted, two data sets, namely MIMIC-IV and eICU-CRD, are used, suppurative myocardial injury patients meeting conditions are included, covariants such as baseline features, laboratory inspection results and complication information of the patients are collected, the patients are divided into two groups according to RAR medians, the relation between RAR and short-term death of the patients is analyzed by adopting multiple statistical methods, and the accuracy of the short-term death of the patients is improved. A risk prediction model of short-term death of the patient suffering from the pyotoxic myocardial injury is constructed, so that a clinician can identify the patient suffering from the pyotoxic myocardial injury with high death risk in an early stage, a personalized treatment strategy can be formulated more accurately, the survival rate of the patient suffering from the pyotoxic myocardial injury is increased, and the method has a wide application prospect.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Acoustophoretic analyzation devices and methods

Fluid analyzation devices, methods, and systems are disclosed including an analyzation device comprising a sample vessel having an outer surface, a microchannel within the confines of the outer surface, a first port extending through the outer surface to the microchannel, and a second port extending through the outer surface to the microchannel; and an piezo transducer bonded to the outer surface of the sample vessel to form a monolithic structure, the piezo transducer configured to emit ultrasonic acoustic waves having a first frequency, a second frequency, and a third frequency into and / or to a blood sample within the microchannel, the first frequency configured to begin separation of red blood cells and plasma in the blood sample, the second frequency configured to complete separation of the red blood cells and plasma, and the third frequency configured to rupture cell walls of the blood cells producing a lysed blood sample.
Owner:SIEMENS HEALTHCARE DIAGNOSTICS INC

Image-based blood flow velocity measurement method, system, device, product and medium

The invention relates to the technical field of image processing, and provides an image-based blood flow velocity measurement method, system and device, a product and a medium, and the method comprises the steps: selecting a to-be-measured capillary; selecting a first position and a second position on the capillary to be measured, and measuring a horizontal azimuth difference and a vertical azimuth difference; respectively obtaining a first red blood cell image number and a second red blood cell image number, and calculating a red blood cell interval difference according to the first red blood cell image number and the second red blood cell image number; constructing a first motion equation and a second motion equation, and resolving through the first motion equation and the second motion equation to obtain a red blood cell velocity relationship; and constructing a differential relational expression of the red blood cell acceleration, substituting the red blood cell velocity relation and the second motion equation into the differential relational expression to obtain a target differential equation, and resolving the target differential equation to obtain the blood flow velocity. The blood flow velocity can be conveniently measured.
Owner:SHANDONG UNIV

Systems and methods for optimizing plasma collection volume

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.
Owner:FENWAL INC

HCT prediction method and system, device, and medium

Disclosed in the present application are an HCT prediction method and system, a device, and a medium. Photons in a photon group are emitted into an extracorporeal circulation blood model so that the photons are reflected, scattered, or absorbed during movement. The extracorporeal circulation blood model is a model constructed on the basis of the thickness of an extracorporeal circulation tube, the thickness of the blood, and the distance from a light source generator to a detector. Light intensity data corresponding to photons reaching the detector are acquired. The acquired light intensity data are input into a prediction model to obtain a hematocrit (HCT) prediction value. The prediction model is a model constructed on the basis of a BP neural network and the relationship between light intensity and HCT. The prediction model combining simulation and neural network increases the data volume, achieves continuous non-invasive estimation of HCT by means of algorithm model optimization, and improves the accuracy of HCT prediction.
Owner:BEIJING AEROSPACE CHANGFENG CO LTD

ALK2 antibodies and methods of use thereof

The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and / or cardiac fibrosis.
Owner:KEROS THERAPEUTICS INC

Autologous platelet-containing plasma gel as well as preparation method and application thereof

The invention provides autologous platelet-containing plasma gel and a preparation method and application thereof, and relates to the technical field of biological medicine and tissue engineering.The preparation method comprises the following steps that peripheral venous blood of a patient is extracted and added into a centrifugal tube mixed with a sodium citrate anticoagulant; putting the centrifugal tube into a centrifugal machine for centrifuging, and taking upper-layer plasma; wherein the upper-layer plasma refers to plasma between the upper-layer liquid level and the lower-layer red blood cell layer by 1mm; the centrifugal speed ranges from 1300 r / min to 1700 r / min; the centrifugation time is 3-5 min; under a sterile condition, preparing a calcium gluconate / thrombin mixed solution; and dropping the calcium gluconate / thrombin mixed solution into the upper plasma, mixing, and solidifying to obtain the autologous platelet-containing plasma gel. After one-time centrifugation, upper-layer full-layer plasma is extracted, the volume of the prepared gel is far larger than that of a traditional method, the utilization rate of whole blood platelets and fibrinogen is close to 100%, and regeneration and repair of large-area tissue wounds can be met.
Owner:揭阳市人民医院

A traditional Chinese medicine composition for clearing away heat, removing blood stasis, stopping bleeding and regulating menstruation and its preparation method

ActiveCN117582468BOrganic active ingredientsSexual disorderAucubinExcessive menstrual flow
The present invention provides a traditional Chinese medicine composition for clearing heat, removing blood stasis, stopping bleeding and regulating menstruation, and a preparation method thereof, relating to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition of the present invention comprises the following components: catalpol, aucubin, β-sitosterol, emodin, chrysophanol, sanguisorba officinalis extract, Panax notoginseng saponins, septamine, cuttlefish scaly, rubiacin, typhaneuroside, and p-coumaric acid; the components synergistically work together to significantly reduce plasma prothrombin time and plasma recalcification time, and significantly reduce the whole blood viscosity, plasma viscosity, and hematocrit of rats with blood stasis syndrome. The traditional Chinese medicine composition of the present invention is used in the preparation of drugs for menstrual disorders or menstrual bleeding and metrorrhagia, and has a significant therapeutic effect on irregular menstruation, excessive menstrual bleeding, or metrorrhagia.
Owner:JIANGXI POZIN PHARMA

Preparation method of macaca fascicularis liver tissue single-cell suspension

The invention belongs to the technical field of biology, and particularly relates to a preparation method of macaca fascicularis liver tissue single-cell suspension. The method comprises the following steps: cleaning macaca fascicularis liver tissues with a pre-cooling buffer solution, and processing into tissue fragments; mixing the tissue fragments with a digestion solution, wherein the digestion solution comprises collagenase I with the final concentration of 1 + / -0.2 mg / ml, collagenase II with the final concentration of 1 + / -0.2 mg / ml, bovine serum albumin with the final concentration of 0.04 + / -0.01% (w / v), DNase I with the final concentration of 10 + / -2 U / ml and the balance of a buffer solution; oscillating and incubating for 30 + / -10min under the conditions of 37 + / -2 DEG C and 150 + / -50rpm, and performing tissue digestion; centrifuging the digested suspension, removing the supernatant, resuspending with a buffer solution, and filtering with a cell sieve to obtain a single-cell primary suspension; and carrying out red blood cell lysis, washing and resuspension on the single-cell primary suspension to prepare the cynomolgus monkey liver tissue single-cell suspension. The method significantly improves the tissue dissociation efficiency, reduces cell adhesion and fragments, effectively protects cell surface antigen epitopes, and has the advantages of simple operation, economy and high efficiency.
Owner:JOINN LAB (SUZHOU) INC

Activin receptor type IIA variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.
Owner:KEROS THERAPEUTICS INC

Sample analysis apparatus and control method thereof

The invention is applicable to the field of in vitro diagnostic equipment, and discloses sample analysis equipment and a control method of the sample analysis equipment, the sample analysis equipment comprises a sample measuring device, a camera device, a display device and a control device, the display device is used for displaying a first interface, and the control device is used for controlling the camera device. The first interface is used for displaying a first target image obtained by shooting the sample container according to the camera device; and displaying a second target image obtained by shooting the sample container according to the camera device, information used for representing a hematocrit detection result of the blood sample, information used for representing a clot detection result of the blood sample, and information used for representing a liquid amount detection result of the blood sample. The information is at least one of information for representing a hemolysis detection result of the blood sample, information for representing a jaundice detection result of the blood sample, and information for representing a lipid detection result of the blood sample. According to the invention, the efficiency and intuition of blood sample quality auditing are improved.
Owner:BEIJING PRECIL INSTR CO LTD +1

Hemodialysis membrane with self-anticoagulation function and preparation method thereof

The invention discloses a hemodialysis membrane with a self-anticoagulation function and a preparation method of the hemodialysis membrane. The hemodialysis membrane with the self-anticoagulation function is obtained by modifying natural polymer fibrin, polydopamine and a sulfonic acid type polymer solution. The hemodialysis membrane is any one or more of a polysulfone membrane, a polyether sulfone membrane, a polyvinylidene fluoride membrane, a polymethyl methacrylate membrane, a polyacrylonitrile membrane, a polyamide membrane, a polyvinyl alcohol membrane, a cellulose acetate membrane and a polypropylene membrane. The invention is used for treating acute and chronic kidney diseases, has good biocompatibility, and shows good blood compatibility in the aspects of inhibiting protein adsorption, platelet adsorption and red blood cell adsorption, reducing hemolysis rate, prolonging blood coagulation time and the like. And the risk of thrombosis caused by improper use of an anticoagulant in a continuous anticoagulation treatment process can be effectively avoided, and the living quality and the survival time of a hemodialysis patient are effectively improved and prolonged.
Owner:成都欧赛医疗器械有限公司

Anti-hypoxia application of rubber tree seed oil

The invention relates to the field of medicines, in particular to anti-hypoxia application of rubber tree seed oil. According to the present invention, the hevea brasiliensis seed oil is disclosed for the first time, such that the hevea brasiliensis seed oil has effects of red blood cell quantity increasing, blood oxygen carrying capacity improving and body hypoxia effectively relieving, and pharmacodynamic research results show that the hevea brasiliensis seed oil can significantly improve the hypoxia tolerance time of mice, has significant anti-hypoxia effect, and can be used for preparing the anti-hypoxia drug. The discovery has great influence on anti-hypoxia research and treatment of the rubber tree seed oil, and has remarkable social value and market value.
Owner:XISHUANGBANNA HUAKUN BIOTECH CO LTD

Platelet-rich plasma preparation device

The utility model discloses a blood platelet rich plasma preparation device which comprises a middle sleeve, an upper storage body, an upper storage cover, a lower storage body and a lower storage cover, a hyperbolic PRP channel and a hyperbolic red blood cell channel are arranged in the upper storage body and the lower storage body respectively, an upper locking bolt and a lower locking bolt are fixed in the middle sleeve, and after the upper locking bolt and the PRP channel are locked in a matched mode, the upper locking bolt and the lower locking bolt are locked in a matched mode. The upper storage body and the upper storage cover form a PRP storage chamber, after the lower locking bolt and the red blood cell channel are matched and locked, the lower storage body and the lower storage cover form a red blood cell storage chamber, the middle sleeve is a plasma storage chamber, a PRP suction opening is formed in the upper storage cover, and the required PRP amount is accurately extracted through the suction opening through the needle head. According to the blood separation device, two times of centrifugal separation can be carried out under the condition that blood is not exposed to air, the blood separation concentration is high, and the PRP extraction amount is accurate.
Owner:CHANGZHOU TAIMEIRUI BIOTECHNOLOGY CO LTD

Kawasaki disease coronary artery disease risk dynamic prediction algorithm and automatic upgrading system

PendingCN120496817AEnsemble learningHealth-index calculationDiseaseCoronary artery dilatation
The invention provides a Kawasaki disease coronary artery disease risk dynamic prediction algorithm and an automatic upgrading system. The Kawasaki disease coronary artery lesion risk dynamic prediction algorithm and the automatic upgrading system comprise the following steps: a, acquiring clinical data of a Kawasaki disease child patient, including data of disease date, sex, month age, serum sodium level, D dimer, erythrocyte distribution width, prothrombin time and C-reactive protein biomarker; according to the Kawasaki disease coronary artery disease risk dynamic prediction algorithm and the automatic upgrading system, through combination of clinical features and gene data of Kawasaki disease children patients, a plurality of machine learning algorithms are used, and an efficient and accurate CAL risk prediction model is constructed. The model combines a plurality of key clinical indexes such as serum sodium level, CRP and D dimer and gene data such as SNP markers such as SIGLEC8-CEACAM18 and PPP1R1C, and the sensitivity and specificity of risk prediction are remarkably improved.
Owner:CHILDRENS HOSPITAL OF FUDAN UNIV

Blood Separator Operation Control Graphical User Interface for Electronic Devices (XJ-III)

1. Name of the product of this design: Graphical user interface for operation control of blood separator for electronic equipment (XJ‑III). 2. Purpose of this design product: used in an electronic device. 3. The key design point of this design product lies in the content displayed in the graphical user interface. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The electronic equipment is of conventional design and other views are omitted. 6. Purpose of the graphical user interface: The product interface is used to operate and control the blood separator. Through human-computer interaction, users can realize equipment self-test, plasma separation, red blood cell separation, PRP separation, consumables installation, information entry, parameter setting, plasma collection, etc. 7. Human-computer interaction mode of the graphical user interface: click "Device Self-Test" in the main view, the interface jumps to interface change state diagram 1; click "Confirm" in interface change state diagram 1, the interface jumps to interface change state diagram 2; click "Plasma Separation" in interface change state diagram 2, the interface jumps to interface change state diagram 3; click "Pre-charge" in interface change state diagram 3, the interface jumps to interface change state diagram 4; click "Next" in interface change state diagram 4, the interface jumps to interface change state diagram 5; click "Confirm" in interface change state diagram 5, the interface jumps to interface change state diagram 6; click "Stop" in interface change state diagram 6, the interface jumps to interface change state diagram 7. In addition, the cross in the interface represents replaceable text and / or numbers and / or letters and / or symbols.
Owner:QINGDAO HAIER BIOMEDICAL TECH CO LTD +1

Preparation device of platelet-rich plasma suspension containing blood cells and gel

The utility model discloses a device for preparing platelet-rich plasma suspension and gel containing blood cells. Comprising a fixing frame, at least one rapid clamping pipe clamp installed on the fixing frame, a vacuum centrifugal pipe clamped in the rapid clamping pipe clamp, and two suction devices capable of being inserted into the centrifugal pipe from the top or the bottom of the centrifugal pipe. The pusher is used for pushing the aspirator to be inserted into the centrifugal tube; the rotating mechanism is used for driving the pusher to rotate so as to enable the aspirator to face the top or the bottom of the centrifugal tube; the utility model solves the problems of blood pollution, manual operation error and low extraction rate in the manual operation process in the prior art, retains all blood platelets and white blood cells in the blood, retains red blood cells in normal proportion and most plasma proteins, and improves the extraction efficiency. Moreover, the concentration of platelets and leukocytes is constantly about 4 times of the concentration of blood of common normal people, the functions of erythrocyte components are reserved, and the functional effects of various components in the blood can be better exerted.
Owner:SHAOGUAN FIRST PEOPLES HOSPITAL (MUNICIPAL INST OF CARDIOVASCULAR DISEASES MUNICIPAL INST OF ORTHOPEDICS)

Hypoperfusion oxyhemoglobin saturation detection method based on dynamic light compensation

The invention relates to a hypoperfusion oxyhemoglobin saturation detection method based on dynamic light compensation, which comprises the following steps of: constructing a combined characteristic relation based on multi-wavelength reflection intensity and fluctuation amplitude, and dynamically judging the optical sparseness of tissues, namely optical characterization of erythrocyte density in the tissues; reversely deducing the current perfusion degree through the morphological characteristics of the reflection waveform; establishing a perfusion optical index; analyzing the dynamic change trend of light reflection in a past period of time by adopting a time sequence modeling mode; an LED driving strategy is dynamically adjusted, and a light supplementing behavior similar to a physiological rhythm is formed in a step-by-step climbing mode, a pulse stimulation mode and a period maintaining mode; each light supplementing action is regarded as physiological stimulation; dynamic form similarity discrimination is introduced, whether tissue response is really caused by light supplement each time is quantified, and real physiological fluctuation and noise disturbance are distinguished; for low-response light supplement, the light supplement intensity is reduced in a feedback manner; on the contrary, key deformation features are extracted from high-response light supplement for signal reconstruction, and the signal recognition capability in the low-perfusion environment can be enhanced.
Owner:ZHEJIANG UNIV